Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 12/20 | 0.45 |
| ▸ | PPARA | Q07869 | 7/20 | 0.45 |
| ▸ | PPARG | P37231 | 7/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5221031 | 0.92 | PPARD (0.52) | PPARDPPARAPPARGPTPN1 | |
| SCHEMBL5216174 | 0.87 | PPARD (0.56) | PPARDPPARAPPARGPTPN1 | |
| SCHEMBL5217157 | 0.87 | PPARD (0.56) | PPARDPPARAPPARGPTPN1 | |
| SCHEMBL5221743 | 0.87 | PPARD (0.56) | PPARDPPARAPPARGPTPN1 | |
| SCHEMBL5852591 | 0.86 | PPARA (0.45) | PPARDPPARAPPARGPTPN1S1PR1 | |
| SCHEMBL5850733 | 0.84 | PPARA (0.41) | PPARDPPARAPPARG | |
| SCHEMBL5218950 | 0.82 | PPARD (0.37) | PPARDPPARAPPARGMAPT | |
| SCHEMBL4471154 | 0.79 | PPARD (0.59) | PPARDPPARAPPARGPTPN1 | |
| SCHEMBL4476993 | 0.79 | PPARD (0.59) | PPARDPPARAPPARGPTPN1 | |
| SCHEMBL4469255 | 0.79 | PPARD (0.59) | PPARDPPARAPPARGPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480640-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |
| US-7153878-B2 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20050107449-A1 | Peroxisome proliferator activated receptor modulators | ELILILLY AND COMPANY | 2005-05-19 | — | — | US | disclosed |
| EP-1480640-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003072100-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107449-A1 | Peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | PPARD 3/4885PPARA 2/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.